Kun Sun

Kunsun is a Shanghai-based biotechnology company specializing in the development of next-generation liquid biopsy technologies for early cancer detection. Founded by pioneers in the field of fragmentomics, the company leverages cell-free DNA (cfDNA) fragmentation patterns to identify cancer-specific signals with high sensitivity and specificity. Kunsun's primary focus is on developing non-invasive screening tests for high-incidence cancers, including liver and lung cancer, as well as multi-cancer early detection (MCED) solutions. The company's proprietary platform integrates advanced sequencing techniques with machine learning algorithms to analyze the fragmentome of cfDNA. Kunsun aims to transform oncology care by providing accessible and accurate tools for early diagnosis, potentially improving patient outcomes through timely intervention.